

Personal Data:

Name: Yu-Li Liu

Gender: Female

Center for Neuropsychiatric Research

National Health Research Institutes

35, Keyan Road, Zhunan Town,

Miaoli County 350, TAIWAN, ROC

Phone: (886)-2-2653-4401 ext 36716

Fax: (886)-37-586-453

E-Mail: ylliou@nhri.org.tw

Education:

Ph.D. – Pharmacology, East Tennessee State University, U.S.A. (Aug-1992 – Dec-1997)

Master – Pharmacology, National Yang-Ming Medical College, TAIWAN. (Sep-1985 – Jun-1987)

Training Experiences:

Investigator, Oct 2017-Present

Center for Neuropsychiatric Research, National Health Research Institutes, Miaoli, Taiwan

Associate Investigator, Oct 2011 – Sep 2017,

Center for Neuropsychiatric Research, National Health Research Institutes, Miaoli, Taiwan

Assistant Investigator, Jul 2007 – Sep 2011,

Division of Mental Health and Addiction Medicine, Institute of Population Health Sciences,
National Health Research Institutes, Miaoli, Taiwan

Research Associate, Mar 2006 – Jun 2007,

Division of Mental Health and Addiction Medicine, Institute of Population Health Sciences,
National Health Research Institutes, Miaoli, Taiwan

Postdoctor, Jan 2002 – Mar 2006,

Department of Medical Research/Psychiatry, National Taiwan University Hospital, Taipei, Taiwan

Clinical Researcher, Jan 2001 – Dec 2001,

Department of Education and Research, Shin Kong WHS Memorial Hospital, Taipei, Taiwan

License and Membership:

Licensed Pharmacist of Taiwan

Member of the Pharmacological Society in Taiwan

Member of World Congress on Psychiatric Genetics

Director of Taiwan Society of Biological Psychiatry and Neuropsychopharmacology

Major awards and honors

2018 獲選第八屆台灣生物精神醫學暨神經精神藥理學學會理事

- 2018 Speaker for 國立政治大學神經科學研究所
- 2018 2nd Innovations and State of the Art in Dementia Research (ISADR-2018), Valencia, Spain
- 2018 Speaker for 中國醫藥大學藥學系 60 周年論壇
- 2018 國衛院優秀助理選拔-劉佳貞小姐
- 2017 科技部「未來科技展」生技與新藥「未來科技突破獎」- 以人工智慧技術開發可治療思覺失調症相關症狀之新型 NMDA 受體調節劑，並榮獲「未來科技突破獎」。
- 2017 Speaker for 5th Asia-Pacific Society for Alcohol and Addiction Research (APSAAR) Taiwanese society of addiction science
- 2017 Speaker for Neural Protection and Regeneration Symposium
- 2017 國衛院優秀助理選拔-郭湘維小姐
- 2016 第十三屆國家新創獎-學研新創獎【製藥及新醫療技術組】
- 2015 Second place award in Taiwan Tech Trek-孫世亞先生
- 2015 國衛院優秀助理選拔-劉聖文小姐
- 2014 國衛院優秀助理選拔-劉淑芝小姐
- 2013 Poster oral presentation for XXI World Congress on Psychiatric Genetics
- 2013 First place award in Taiwan Tech Trek-鍾介恆先生
- 2013 國衛院優秀助理選拔-方秋萍小姐
- 2011 國衛院優秀助理選拔-郭湘維小姐
- 2011 Poster Award Finalists in 4th Asian Pacific Regional Meeting of ISSX (International Society for the Study of Xenobiotics).
- 2009 Best Poster Presentation in TDM at the 11th IATDMCT (International Association of Therapeutic Drug Monitoring and Clinical Toxicology) congress.

Representative Publications:

1. Wang, SC, Chung, RH, Huang, CL, Kuo, HW, Liu, TH, Ho, IK, Liu, SC, Fang, CP, Chen, ACH, Hsiao, CF, Chang, YS, Liu, CC, Liu, YL (correspondence) (2018) GRK5 is Associated with the regulation of methadone dosage in heroin dependence. *Int. J. Neuropsychopharmacol.* 21(10):910-917.
2. Liu, CC, Fang, CP, Liu, TH, Kuo, HW, Liu, SC, Wang, SC, Chen, ACH, Liu, YL (correspondence) (2018) APBB2 is associated with amphetamine use and plasma beta-amyloids in patients receiving methadone maintenance treatment. *Prog. Neuropsychopharmacol. Biol. Psychiatry.* 83: 92-98.
3. Kuo, HW, Liu, TH, Tsou, HH, Hsu, YT, Wang, SC, Fang, CP, Liu, CC, Chen, ACH, Liu, YL (correspondence) (2018) Inflammatory chemokine eotaxin-1 is correlated with age in heroin dependent patients under methadone maintenance therapy. *Drug Alcohol Depend.* 183:19-24.
4. Liu, TH, Chung, RH, Wang, SC, Fang, CP, Tsou, HH, Shih, CL, Kuo, HW, Wang, Y, Liu, YL (correspondence) (2017) Missense mutation at CLDN8 associated with a high plasma

- interferon gamma-inducible protein 10 level in methadone-maintained patients with urine test positive for morphine. *PLoS One* 12(11):e0187639.
5. Yang, HC, Chu, SK, Huang, CL, Kuo, HW, Wang, SC, Liu, SW, Ho, IK, Liu, YL (correspondence) (2016) Genome-wide pharmacogenomic study on methadone maintenance treatment identifies SNP rs17180299 and multiple haplotypes on CYP2B6, SPON1, and GSG1L associated with plasma concentrations of methadone R- and S-enantiomers in heroin-dependent patients. *PLoS Genet.* 12(3): e1005910.
 6. Liu, SW, Liu, YL, Hwang, LL, Wang, SC, Kuo, HW, Wu, SL, Dai, YWE, Liu, SC, Ho, IK, Chen, ACH, Hsiao, CF, Tsou, HH (2015) Chemokine IP-10 is correlated with cardiac responses and status of infection with HIV and HCV in methadone maintenance patients. *Int. J. Cardiol.* 194:36-38.
 7. Wang, SC, Tsou, HH, Chung, RH, Chang, YS, Fang, CP, Chen, CH, Ho, IK, Kuo, HW, Liu, SC, Shih, YH, Wu, HY, Huang, BH, Lin, KM, Chen, AC, Hsiao, CF, Liu, YL (correspondence) (2014) The association of genetic polymorphisms in the kappa-opioid receptor 1 gene with body weight, alcohol use, and withdrawal symptoms in patients with methadone maintenance. *J. Clin. Psychopharmacol.* 34(2): 205-211.
 8. Wang, SC, Tsou, HH, Ho, IK, Lin, KM, Liu, YL (correspondence) (2013) Pharmacogenomics study in a Taiwanese methadone maintenance cohort. *J. Food Drug Anal.* 21: S62-68.
 9. Wu, SL, Wang, SC, Tsou, HH, Kuo, HW, Ho, IK, Liu, SW, Hsu, YT, Chang, YS, Liu, YL (correspondence) (2013) Hepatitis C virus infection influences the S-methadone metabolite plasma concentration. *PLoS One* 8(7): e69310.
 10. Chen, YT, Tsou, HH, Kuo, HW, Fang, CP, Wang, SC, Ho, IK, Chang, YS, Chen, CH, Hsiao, CF, Wu, HY, Lin, KM, Chen, ACH, Tsai-Wu, JJ, Liu, YL (correspondence) (2013) *OPRM1* genetic polymorphisms are associated with the plasma nicotine metabolite cotinine concentration in methadone maintenance patients: a cross sectional study. *J. Hum. Genet.* 58(2): 84-90.
 11. Wang, SC, Tsou, HH, Chen, CH, Chen, YT, Ho, IK, Hsiao, CF, Chou, SY, Lin, YF, Fang, KC, Huang, CL, Su, LW, Fang, YC, Liu, ML, Wu, HY, Lin, KM, Liu, SC, Kuo, HW, Chiang, IC, Chen, AC, Tian, JN, Liu, YL (correspondence) (2012) Genetic polymorphisms in the opioid receptor mu1 gene are associated with changes in libido and insomnia in methadone maintenance patients. *Eur. Neuropsychopharmacol.* 22(10): 695-703.
 12. Lin, SK, Chen, CK, Liu, YL (2011) Aripiprazole and dehydroaripiprazole plasma concentrations and clinical responses in patients with schizophrenia. *J. Clin. Psychopharmacol.* 31(6): 758-762.
 13. Lin, KM, Chiu, YF, Tsai, IJ, Chen, CH, Shen, WW, Liu, SC, Lu, SC, Liu, CY, Hsiao, MC, Tang, HS, Liu, SI, Chang, LH, Wu, CS, Tsou, HH, Tsai, MH, Chen, CY, Wang, SM, Kuo, HW, Hsu, YT, Liu, YL (correspondence) (2011) ABCB1 gene polymorphisms are associated with the severity of major depressive disorder and its response to escitalopram treatment.

Pharmacogenet. Genomics 21(4): 163-170.

14. Liu, YL, Fann, CSJ, Liu, CM, Chen, WJ, Wu, JY, Hung, SI, Chen, CH, Jou, YS, Liu, SK, Hwang, TJ, Hsieh, MH, Chang, CC, Yang, WC, Lin, JJ, Chou, FHC, Faraone, SV, Tsuang, MT, Hwu, HG (2008) RASD2, MYH9, and CACNG2 genes at chromosome 22q12 associated with the subgroup of schizophrenia with non-deficit in sustained attention and executive function. *Biol. Psychiatry* 64(9): 789-796.
15. Liu, YL, Fann, CSJ, Liu, CM, Chang, CC, Yang, WC, Hung, SI, Yu, SL, Hwang, TJ, Hsieh, MH, Liu, CC, Tsuang, MM, Wu, JY, Jou, YS, Faraone, SV, Tsuang, MT, Chen, WJ, Hwu, HG (2007) More evidence supports the association of PPP3CC with schizophrenia. *Mol. Psychiatry* 12(10): 966-974.